{"id":2252,"date":"2023-07-18T19:58:27","date_gmt":"2023-07-18T23:58:27","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/a-novel-platform-combining-transcriptomics-and-interaction-proteomics-to-better-define-personalized-medicine-in-cancer\/"},"modified":"2024-09-25T16:25:39","modified_gmt":"2024-09-25T20:25:39","slug":"a-novel-platform-combining-transcriptomics-and-interaction-proteomics-to-better-define-personalized-medicine-in-cancer","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/a-novel-platform-combining-transcriptomics-and-interaction-proteomics-to-better-define-personalized-medicine-in-cancer\/","title":{"rendered":"A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer"},"content":{"rendered":"\n

Challenge:<\/strong> In the last decade, cancer genomics has shown that not all\u00a0patient tumours are identical, and conversely that they will not respond similarly to anticancer agents. The key, therefore, is personalized (or precision) medicine whereby specific drugs will be given to a patient carrying a gene that will make their tumours sensitive to such drugs.
However, the identification of genes expressing proteins that could\u00a0represent therapeutic targets still remains elusive in many cancers.<\/p>\n\n\n\n

Solution:<\/strong> The team developed quantitative Transcriptome and Affinity-Proteomics (qTAP), a transformative diagnostic platform that integrates\u00a0quantitative interaction proteomics with whole transcriptomics to provide a\u00a0global view of an individual patient\u2019s tumour. The platform allows the\u00a0analysis of the human protein network, providing a functional 3D view of\u00a0protein-protein interactions in patient tumours. Such molecular information\u00a0will make it possible to identify drugs that are most effective at treating specific cancers. As a proof of concept, the team used this technology to\u00a0identify candidate peptides to inhibit important nodes of the Smurf and\u00a0Hippo signaling pathways, which are involved in multiple drug resistance in\u00a0cancer.<\/p>\n\n\n\n

Achievements\/Impact:<\/strong>\u00a0At completion of the project, the team successfully\u00a0provided tools to analyze and probe patient tumors, including (i) affinity-purified mass spectrometry (AP-MS)-based proteomics strategies to map\u00a0the dynamic state of signaling networks in vivo and (ii) qTAP to instruct\u00a0single and combined targeted therapeutic strategies. The project also led to\u00a0the identification of small molecule antagonists for the morphogen\u00a0pathways, Smurf and Hippo pathways, that could be further investigated.
These technologies offer new avenues for the discovery of novel therapeutic targets for treating patients whose tumors fail to respond to existing\u00a0therapies and understanding the drug resistance mechanisms.<\/p>\n\n\n\n

Principal Investigator:<\/strong>
Jeff Wrana<\/strong>
LTRI, Mount Sinai
Hospital<\/td><\/tr>
Co-Investigators:<\/strong>
Anne-Claude Gingras,
Alexandre Zlotta<\/strong>
LTRI, Mount Sinai
Hospital
Andrei Yudin<\/strong>
University of Toronto
Andrew Roughton<\/strong>
Encycle Therapeutics Inc.
Azar Azad<\/strong>
Mount Sinai Hospital
<\/strong>Services<\/td><\/tr>
Completed <\/strong><\/strong><\/strong>Project<\/strong><\/td><\/tr>
$1,030,000 \/ 2 years<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/td><\/tr>
Supported by CQDM through:<\/strong>
– Merck
– Pfizer
– BL-NCE<\/td><\/tr>
And by co-founding partners:<\/strong>
<\/strong>– CIHR
– Encycle Therapeutics Inc.
– Mount Sinai Hospital Services<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

Challenge: In the last decade, cancer genomics has shown that not all\u00a0patient tumours are identical, and conversely that they will not respond similarly to anticancer agents. The key, therefore, is personalized (or precision) medicine whereby specific drugs will be given to a patient carrying a gene that will make their tumours sensitive to such drugs.However,…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2252","post","type-post","status-publish","format-standard","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2252"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2252\/revisions"}],"predecessor-version":[{"id":4788,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2252\/revisions\/4788"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}